This page was designed to be viewed with a browser that supports Cascading Style Sheets [CSS] and if you are using earlier versions [pre- ver.5.0] of Internet Explorer or Netscape Navigator,you are missing out on a pleasant viewing experience. It is best that you upgrade your browser soon as most of the sites will increasingly make use of CSS.

 gniLogo GoodNewsIndia :: The GoodNews Sieve

GoodNews sieved from mainstream media output



Prev: Workers in management  |  Next: Nepa Mills recycles newspapers



Sep 25, 2006 :: Affordable Hepatitis-B vaccine

Indian pharma entrepreneurs competing with world majors is familiar news by now. But here’s a surprise player: the National Dairy Development Board [NDDB]. It has launched Elovac-B, its branded, low-cost vaccine for humans against Hepatitis-B. Human Biologicals Institution, a division under NDDB’s wholly owned manufacturing arm, Indian Immunologicals Ltd will produce the vaccine. Elovac is said to be 40% of the cost of similar products from Indian and MNC pharma companies. About 200 million doses are expected to be manufactured and distributed mostly through its own countrywide network of 2,000 clinics.

NDDB is also working on measles, DPT, TT and combination vaccines. Links to story and NDDB

-->

HOME
Directories:: Magazine◊Supplements◊Backstage
-->" target="_blank" class="services"> Send This Story To Friends
Print




GNI Mailing List
Sign UpLeave

Write to GoodNewsIndia

Browse the Sieve collection